ZIOP-PGEN Fundamental & Technical Discussion Board - Competitors in TCR-T -- Iova, Intellia, TCRR and Timmunity - ZIOP-PGEN Fundamental & Technical Discussion Board - InvestorVillage


ZIOP-PGEN Fundamental & Technical Discussion Board
This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: ZIOP-PGEN Fundamental & Technical Discussion Board   /  Message Board  /  Read Message

 
 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  25207 of 25524  at  10/28/2021 12:17:24 AM  by

dnmun


 In response to msg 25205 by  dachmeister4u
view thread

Re: Competitors in TCR-T -- Iova, Intellia, TCRR and Timmunity

a naive lymphocyte is one which has not been presented with the specific antigen/HLA complex that the TCR of that lymphocyte was created 'randomly' by the recombinase of the thymus that creates the TCR randomly.
 
so the naive peripheral lymphocyte is one which has not been activated by that binding of it's TCR to the tetramer made of the MHC-epitope complex with the epitope held in the grasp of the MHC like a sausage laying in the mitt of a glove, (the alpha and beta chains are the glove).
 
so naive means it just has not had the replication of the lymphocyte activated by binding of it's native TCR to the tetramer.
 
so since it has not already been activated, then it can be used to create the synthetic lymphocyte by gene editing, in our case using the transposase, in dr Rosenberg's group they used the retrovirus to add the new TCR coding.
 
both us and dr Roseberg use the mouse beta chains to create the TCR. the alpha and beta chains are what is used for the specific TCR. by using the mouse beta chains, there is no recombination of the original naive lymphocyte's coding for the TCR,  because the original alpha and beta chains when bound to the mouse beta chains, they are not able to be activated so there is only one combo out of the three possibilities which will be activated when returned to the patient and recognize the tumor antigenic epitope/MHC combo. 
 
that causes the newly created lymphocyte to become activated by exposure to it's binding tetramer. and nothing else.
 
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 6  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
25208 Re: Competitors in TCR-T -- Iova, Intellia, TCRR and Timmunity dachmeister4u 3 10/28/2021 9:53:06 AM


Financial Market Data provided by
.
Loading...